Ginkgo Bioworks Partners with CMU to Develop Innovative Cancer Detection Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: PRnewswire
- Collaborative Innovation: Ginkgo Bioworks partners with Carnegie Mellon University to secure funding from ARPA-H for the POSEIDON project, aiming to develop an innovative oral pill and user-friendly at-home cancer screening device, which is expected to significantly enhance early cancer diagnostic accuracy.
- Technological Breakthrough: The new pill will combine synthetic biology and nucleic acid nanotechnology to utilize tumor-targeting sensors for detecting cancer hallmarks like low oxygen and acidity, thereby providing disease signals through a simple urine test, potentially transforming traditional cancer detection methods.
- Multidisciplinary Team: The project team includes academic experts from the University of Pittsburgh, the University of Massachusetts Amherst, and KU Leuven, with Ginkgo Bioworks serving as the commercial partner, highlighting the importance of interdisciplinary collaboration in the biomedical field.
- Market Potential: By offering more precise cancer detection tools, Ginkgo Bioworks not only enhances its competitiveness in the biotechnology market but also has the potential to drive the adoption of early cancer diagnostics, improving treatment decision-making for patients.
DNA
$8.79+Infinity%1D
Analyst Views on DNA
Wall Street analysts forecast DNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNA is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
0 Hold
2 Sell
Moderate Sell
Current: 8.100
Low
14.00
Averages
14.00
High
14.00
Current: 8.100
Low
14.00
Averages
14.00
High
14.00
About DNA
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
